Medicare
Infliximab biosimilar uptake rapidly increased only after release of a third option
Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.
New eligibility for semaglutide would cost Medicare billions in spending
High BMI eligibility for semaglutide could cost Medicare up to $145 billion annually, a brief report published in the Annals of Internal Medicine revealed.
Corporate walk-in clinic closures 'not at all surprising,' highlight unsustainable system
The closure of walk-in clinics from massive corporations like Walmart and Walgreens is reflective of a primary care system in crisis, according to experts.
Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of August 19, 2024
In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.
Top in endocrinology: Price cuts for Medicare Part D drugs; tirzepatide vs. GLP-1s
Beginning in 2026, prices for 10 drugs will be reduced for Medicare Part D recipients, according to a CMS press release.
Proposed 2025 Medicare Physician Fee Schedule recognizes value of vision care
Proposed changes to the 2025 Medicare Physician Fee Schedule may benefit the field of optometry, according to the American Optometric Association.
Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations
The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.
Medicare announces price cuts for 10 drugs in first round of drug price negotiations
The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.
Dementia diagnosis rates 4% lower for Medicare Advantage enrollees
PHILADELPHIA — An analysis of more than 15 million Americans enrolled in Medicare found that those enrolled in the Medicare Advantage plan had a 4% lower dementia diagnosis rate than those in traditional Medicare, according to a presenter.
The Latest News and Notes, plus Conversation with Cathleen McCabe, MD
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care.